Literature DB >> 9593380

Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy.

T Tyni1, T Kivelä, M Lappi, P Summanen, E Nikoskelainen, H Pihko.   

Abstract

OBJECTIVE: The purpose of the study was to determine the nature and course of ophthalmic abnormalities in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a recently discovered disorder of mitochondrial fatty acid beta-oxidation. STUDY
DESIGN: The study design was a cohort (case series). PARTICIPANTS: A retrospective review of the records of 15 children who had died during their first 2 years was performed. Also performed were a longitudinal reanalysis and cross-sectional clinical examination of four long-term survivors aged 5 to 31 years. MAIN OUTCOME MEASURES: Visual acuity, refraction, visual fields, ophthalmoscopy, fluorescein angiography, biometry, corneal topography, electroretinography (ERG), visual-evoked potentials (VEPs), color vision, and dark adaptation were measured.
RESULTS: In seven children, ophthalmoscopic findings were within normal limits at 3 days to 13 months of age (median, 4.8 months). In 11 children, a granular retinal pigment epithelium (RPE), with or without pigment clumping in the macula, was seen at 4 months to 5 years of age (median, 9 months). Two long-term survivors, 16 and 31 years of age, eventually had circumscribed atrophy of the choroid, RPE, and retina, which coincided with a posterior staphyloma type 1. They had progressive axial myopia starting at 6 and 12 years of age and later paracentral scotomas leading to poor central vision. They suffered from early difficulty with mesopic vision, glare, and a severe generalized color vision deficiency that started as a tritanomaly. A third survivor was mildly myopic at 5 years of age. All four surviving patients had visually insignificant, flake-like supranuclear opacities in the lens. The ERG initially was normal but deteriorated during the first decade and later was unrecordable. The VEP responses remained fairly normal. Initially, angiography showed no blockade of the choroidal fluorescence because of the thin RPE. Filling of choroidal vessels was delayed, and the choriocapillaris and, later, larger choroidal vessels in the posterior pole became nonperfused.
CONCLUSIONS: In LCHAD deficiency, the fundus is normal at birth (stage 1). Soon, however, pigment dispersion occurs in the RPE (stage 2), followed by circumscribed chorioretinal atrophy, occlusion of choroidal vessels, and deterioration of central vision, often with relative sparing of the peripheral fundus (stage 3). Finally, posterior staphylomas and central scotomas may develop (stage 4). Developmental cataract, progressive myopia, and deterioration of visual fields and color vision are new findings in LCHAD deficiency. The chorioretinopathy and abnormal ERG precede the development of myopia and posterior staphyloma, which, in turn, coincide with the loss of macular vision. The authors postulate that the RPE or choriocapillaris is primarily affected. Awareness of the characteristic ocular features is important because of an opportunity for dietary treatment, genetic counseling, and prenatal diagnosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593380     DOI: 10.1016/S0161-6420(98)95019-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

1.  Docosahexaenoic acid and retinal function in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  C O Harding; M B Gillingham; S C van Calcar; J A Wolff; J N Verhoeve; M D Mills
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  Growth in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency.

Authors:  C Bieneck Haglind; M Halldin Stenlid; S Ask; J Alm; A Nemeth; Uv Döbeln; A Nordenström
Journal:  JIMD Rep       Date:  2012-07-06

3.  Follow-up and multimodal imaging in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  Glenda Espinosa-Barberi; Sara Miranda Fernández; Michel Ernesto Valdés Martín; María Ángeles Betancor Perdomo; Carmen Julissa Aguilar Rosales
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

4.  Cryo-EM structure of human mitochondrial trifunctional protein.

Authors:  Kai Liang; Ningning Li; Xiao Wang; Jianye Dai; Pulan Liu; Chu Wang; Xiao-Wei Chen; Ning Gao; Junyu Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-18       Impact factor: 11.205

5.  [Ocular signs of a mitochondrial trifunctional protein defect. A long-term follow-up].

Authors:  T Ach; G Kolling; K Rohrschneider; C Richter; D Haas; A Schmidt-Bacher
Journal:  Ophthalmologe       Date:  2012-03       Impact factor: 1.059

Review 6.  Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening.

Authors:  Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

7.  Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders: Long-Term Follow-up of 21 Cases.

Authors:  Erin A Boese; Nieraj Jain; Yali Jia; Catie L Schlechter; Cary O Harding; Simon S Gao; Rachel C Patel; David Huang; Richard G Weleber; Melanie B Gillingham; Mark E Pennesi
Journal:  Ophthalmology       Date:  2016-08-02       Impact factor: 12.079

8.  Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fast.

Authors:  C Bieneck Haglind; A Nordenström; S Ask; U von Döbeln; J Gustafsson; M Halldin Stenlid
Journal:  J Inherit Metab Dis       Date:  2014-08-21       Impact factor: 4.982

9.  Plasma and erythrocyte fatty acid concentrations in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  A M Lund; M A Dixon; P Vreken; J V Leonard; A A M Morris
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.